Mind Medicine (NASDAQ: MNMD) stock is posting big gains in Tuesday's trading. The biotech company's share price was up 8.7% ...

Mind Medicine (MindMed) MNMD is developing its lead pipeline candidate, MM120, an orally disintegrating tablet (ODT) and a ...

GET MORE AI-GENERATED SIGNALS: December 29, 2024, 13:56 pm ET, BY John- Contributor| Editor: Thomas H. Kee Jr. ( Follow on ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Geode Capital Management LLC boosted its holdings in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Free Report) by 10.8% during ...

Inc. (NASDAQ:MNMD – Get Free Report) shares were down 8.5% on Friday following insider selling activity. The company traded ...

Robert Barrow, the Chief Executive Officer of $MNMD ($MNMD), sold 19,106 shares of the company on 12-26-2024. We received data on the trade from a recent SEC filing ...

Mind Medicine (MNMD) or MindMed announced that the first patient has been dosed in its Phase 3 Voyage study of MM120 ODT, a pharmaceutically optimized form of lysergide D-tartrate LSD or the ...

Oppenheimer analyst Francois Brisebois maintained a Buy rating on Mind Medicine (MNMD – Research Report) today and set a price target of $20.00. The company’s shares closed yesterday at $7.40.